Contribution of hepatocyte nuclear factor-4 to down-regulation of CYP2D6 gene expression by nitric oxide

被引:44
作者
Hara, H [1 ]
Adachi, T [1 ]
机构
[1] Gifu Pharmaceut Univ, Lab Clin Pharmaceut, Gifu 5028585, Japan
关键词
D O I
10.1124/mol.61.1.194
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nitric oxide (NO) released under inflammatory and infectious conditions has been implicated in the down-regulation of many cytochrome P450 genes, but its mechanism of action remains unknown. We showed that the expression of the CYP2D6 gene is down-regulated at the transcriptional level by NO in HepG2 cells. The NO donor (+/-)-N-[(E)-4-ethyl-2-[(Z)-hydroxyiminol-5-nitro-3-hexene-1-yl]-3-pyridine carboxamide (NOR4) decreased the expression of CYP2D6 mRNA in a concentration-dependent manner. Using a CYP2D6 promoter-luciferase construct, we found that NOR4 and another NO donor, S-nitrosoglutathione (GSNO), reduced the luciferase activity in a concentration-dependent manner. A guanylate-cyclase inhibitor failed to prevent suppression of CYP2D6 promoter activity by GSNO, indicating that the activity of the CYP2D6 promoter is suppressed via an NO-guanylate cyclase-independent path-way. Deletion analysis of the CYP2D6 promoter revealed that the -80 to +65 region, which contains the nuclear receptor hepatocyte nuclear factor-4 (HNF4) binding site, was responsible for the suppression of CYP2D6 promoter activity by NO. Therefore, we examined NO responsiveness of the HNF4 binding site by electrophoretic mobility-shift assays and site-direct mutagenesis. The DNA-binding activity of HNF4 was directly inhibited by NO donors, GSNO, and S-nitroso-N-acetyl-penicillamine in a concentration-dependent manner. Mutation of the HNF4 binding site in the CYP2D6 promoter partially restored the suppression of the promoter activity by NO donors. These results demonstrated that NO down-regulates CYP2D6 gene expression, at least in part, by directly inhibiting HNF4 binding to the CYP2D6 promoter.
引用
收藏
页码:194 / 200
页数:7
相关论文
共 40 条
[1]   HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS [J].
ALVAN, G ;
BECHTEL, P ;
ISELIUS, L ;
GUNDERTREMY, U .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) :533-537
[2]   Zinc finger transcription factors as molecular targets for nitric oxide-mediated immunosuppression:: Inhibition of IL-2 gene expression in murine lymphocytes [J].
Berendji, D ;
Kolb-Bachofen, V ;
Zipfel, PF ;
Skerka, C ;
Carlberg, C ;
Kröncke, KD .
MOLECULAR MEDICINE, 1999, 5 (11) :721-730
[3]   Characterization of the human cytochrome P4502D6 promoter - A potential role for antagonistic interactions between members of the nuclear receptor family [J].
Cairns, W ;
Smith, CAD ;
McLaren, AW ;
Wolf, CR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (41) :25269-25276
[4]  
Carlson TJ, 1996, MOL PHARMACOL, V49, P796
[5]  
CHEN D, 1994, J BIOL CHEM, V269, P5420
[6]   GENETICALLY VARIABLE METABOLISM OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS IN MAN [J].
DAHL, ML ;
BERTILSSON, L .
PHARMACOGENETICS, 1993, 3 (02) :61-70
[7]  
Donato MT, 1997, J PHARMACOL EXP THER, V281, P484
[8]   A NEW NITRIC-OXIDE (NO) RELEASER - SPONTANEOUS NO RELEASE FROM FK409 [J].
FUKUYAMA, S ;
KITA, Y ;
HIRASAWA, Y ;
SATO, A ;
MOROKOSHI, N ;
KODA, S ;
YASUDA, T ;
OKA, S ;
SAKURAI, H .
FREE RADICAL RESEARCH, 1995, 23 (05) :443-452
[9]   Inhibition of rat and human cytochrome P4502E1 catalytic activity and reactive oxygen radical formation by nitric oxide [J].
Gergel, D ;
Misik, V ;
Riesz, P ;
Cederbaum, AI .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1997, 337 (02) :239-250
[10]   NITRIC-OXIDE - PATHOPHYSIOLOGICAL MECHANISMS [J].
GROSS, SS ;
WOLIN, MS .
ANNUAL REVIEW OF PHYSIOLOGY, 1995, 57 :737-769